PART I Overview A New Type of Biopharmaceutical Company BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory appro...
Q2 FY2026 — expected 2026-08-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001743881-26-000009 | EDGAR | 152K words |
| 2025-02-20 | 2024-12-31 | 0000950170-25-024119 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018811 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004145 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0000950170-22-002030 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008969 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001564590-20-008260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-29 | 2025-09-30 | 0001743881-25-000012 | EDGAR | 50K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103192 | EDGAR | — |
| 2025-04-29 | 2025-03-31 | 0000950170-25-060314 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124577 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089326 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052165 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058255 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037977 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017812 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021936 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014824 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007874 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001140361-26-011991 | EDGAR | 1K words |
| 2026-02-24 | 0001743881-26-000008 | EDGAR | — |
| 2026-02-12 | 0001140361-26-004995 | EDGAR | — |
| 2026-01-21 | 0001140361-26-001843 | EDGAR | — |
| 2026-01-12 | 0001140361-26-000971 | EDGAR | — |
| 2025-10-29 | 0001140361-25-039705 | EDGAR | — |
| 2025-10-29 | 0001743881-25-000010 | EDGAR | — |
| 2025-10-27 | 0001140361-25-039463 | EDGAR | — |
| 2025-08-05 | 0000950170-25-102985 | EDGAR | — |
| 2025-07-02 | 0001140361-25-024413 | EDGAR | — |
138 total filings indexed. 109 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001743881 |
| Ticker | BBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.bridgebio.com |
| Listed | 2019-06-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report